Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique

Thomas H. Connor, Megan Shults, Matthew Fraser

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

This study evaluated the ability of mutagenic antineoplastic agents to vaporize at room temperature (23°C) and 37°C. A bacterial mutagenicity assay was used to determine the mutagenicity of these agents in the vapor phase. Open plates of bacteria were exposed to varying amounts of drug solutions in sealed glass containers for 24 h. The drug solutions were prepared as they would be for patient treatment and were tested at 0.25, 0.5 and 1.0 ml of each drug solution per 10 l of air. Following exposure, the plates exposed at 23°C were incubated an additional 48 h at 37°C to allow for expression of mutations. Those exposed at 37°C were incubated for an additional 24 h at 37°C. Carmustine, cyclophosphamide, ifosfamide, thiotepa, and mustargen demonstrated vaporization at 37°C. Carmustine and mustargen also demonstrated significant vaporization at 23°C, while cyclophosphamide demonstrated a 50% increase in revertants at this temperature. In addition, sodium azide, a known mutagen used as a control was also mutagenic as a vapor at both temperatures. Doxorubicin, cisplatin, etoposide, 5-fluorouracil and mitomycin were not detected as vaporizing in this assay. The study found that vaporization of standard solutions of some antineoplastic agents is possible at room temperature and increases as the temperature increases. Therefore, vaporization of spilled antineoplastic agents may present an additional route of exposure to healthcare workers through inhalation. (C) 2000 Published by Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
JournalMutation Research - Genetic Toxicology and Environmental Mutagenesis
Volume470
Issue number1
DOIs
StatePublished - Oct 10 2000
Externally publishedYes

Fingerprint

Volatilization
Antineoplastic Agents
Temperature
Carmustine
Mechlorethamine
Cyclophosphamide
Pharmaceutical Preparations
Thiotepa
Sodium Azide
Ifosfamide
Mutagens
Mitomycin
Etoposide
Fluorouracil
Doxorubicin
Inhalation
Cisplatin
Glass
Air
Bacteria

Keywords

  • Antineoplastic agents
  • Occupational exposure
  • Salmonella
  • Vaporization

ASJC Scopus subject areas

  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

@article{3c35591d09d14b09a17e1f7b0ac01393,
title = "Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique",
abstract = "This study evaluated the ability of mutagenic antineoplastic agents to vaporize at room temperature (23°C) and 37°C. A bacterial mutagenicity assay was used to determine the mutagenicity of these agents in the vapor phase. Open plates of bacteria were exposed to varying amounts of drug solutions in sealed glass containers for 24 h. The drug solutions were prepared as they would be for patient treatment and were tested at 0.25, 0.5 and 1.0 ml of each drug solution per 10 l of air. Following exposure, the plates exposed at 23°C were incubated an additional 48 h at 37°C to allow for expression of mutations. Those exposed at 37°C were incubated for an additional 24 h at 37°C. Carmustine, cyclophosphamide, ifosfamide, thiotepa, and mustargen demonstrated vaporization at 37°C. Carmustine and mustargen also demonstrated significant vaporization at 23°C, while cyclophosphamide demonstrated a 50{\%} increase in revertants at this temperature. In addition, sodium azide, a known mutagen used as a control was also mutagenic as a vapor at both temperatures. Doxorubicin, cisplatin, etoposide, 5-fluorouracil and mitomycin were not detected as vaporizing in this assay. The study found that vaporization of standard solutions of some antineoplastic agents is possible at room temperature and increases as the temperature increases. Therefore, vaporization of spilled antineoplastic agents may present an additional route of exposure to healthcare workers through inhalation. (C) 2000 Published by Elsevier Science B.V.",
keywords = "Antineoplastic agents, Occupational exposure, Salmonella, Vaporization",
author = "Connor, {Thomas H.} and Megan Shults and Matthew Fraser",
year = "2000",
month = "10",
day = "10",
doi = "10.1016/S1383-5718(00)00105-4",
language = "English (US)",
volume = "470",
pages = "85--92",
journal = "Mutation Research - Genetic Toxicology and Environmental Mutagenesis",
issn = "1383-5718",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique

AU - Connor, Thomas H.

AU - Shults, Megan

AU - Fraser, Matthew

PY - 2000/10/10

Y1 - 2000/10/10

N2 - This study evaluated the ability of mutagenic antineoplastic agents to vaporize at room temperature (23°C) and 37°C. A bacterial mutagenicity assay was used to determine the mutagenicity of these agents in the vapor phase. Open plates of bacteria were exposed to varying amounts of drug solutions in sealed glass containers for 24 h. The drug solutions were prepared as they would be for patient treatment and were tested at 0.25, 0.5 and 1.0 ml of each drug solution per 10 l of air. Following exposure, the plates exposed at 23°C were incubated an additional 48 h at 37°C to allow for expression of mutations. Those exposed at 37°C were incubated for an additional 24 h at 37°C. Carmustine, cyclophosphamide, ifosfamide, thiotepa, and mustargen demonstrated vaporization at 37°C. Carmustine and mustargen also demonstrated significant vaporization at 23°C, while cyclophosphamide demonstrated a 50% increase in revertants at this temperature. In addition, sodium azide, a known mutagen used as a control was also mutagenic as a vapor at both temperatures. Doxorubicin, cisplatin, etoposide, 5-fluorouracil and mitomycin were not detected as vaporizing in this assay. The study found that vaporization of standard solutions of some antineoplastic agents is possible at room temperature and increases as the temperature increases. Therefore, vaporization of spilled antineoplastic agents may present an additional route of exposure to healthcare workers through inhalation. (C) 2000 Published by Elsevier Science B.V.

AB - This study evaluated the ability of mutagenic antineoplastic agents to vaporize at room temperature (23°C) and 37°C. A bacterial mutagenicity assay was used to determine the mutagenicity of these agents in the vapor phase. Open plates of bacteria were exposed to varying amounts of drug solutions in sealed glass containers for 24 h. The drug solutions were prepared as they would be for patient treatment and were tested at 0.25, 0.5 and 1.0 ml of each drug solution per 10 l of air. Following exposure, the plates exposed at 23°C were incubated an additional 48 h at 37°C to allow for expression of mutations. Those exposed at 37°C were incubated for an additional 24 h at 37°C. Carmustine, cyclophosphamide, ifosfamide, thiotepa, and mustargen demonstrated vaporization at 37°C. Carmustine and mustargen also demonstrated significant vaporization at 23°C, while cyclophosphamide demonstrated a 50% increase in revertants at this temperature. In addition, sodium azide, a known mutagen used as a control was also mutagenic as a vapor at both temperatures. Doxorubicin, cisplatin, etoposide, 5-fluorouracil and mitomycin were not detected as vaporizing in this assay. The study found that vaporization of standard solutions of some antineoplastic agents is possible at room temperature and increases as the temperature increases. Therefore, vaporization of spilled antineoplastic agents may present an additional route of exposure to healthcare workers through inhalation. (C) 2000 Published by Elsevier Science B.V.

KW - Antineoplastic agents

KW - Occupational exposure

KW - Salmonella

KW - Vaporization

UR - http://www.scopus.com/inward/record.url?scp=0034633901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034633901&partnerID=8YFLogxK

U2 - 10.1016/S1383-5718(00)00105-4

DO - 10.1016/S1383-5718(00)00105-4

M3 - Article

VL - 470

SP - 85

EP - 92

JO - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

JF - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

SN - 1383-5718

IS - 1

ER -